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ALL Acute lymphoblastic leukemia 
DFCI Dana-Farber Cancer Institute 
DFCI 05-001 Dana-Farber Cancer Institute ALL Consortium Protocol 05-001 
CCSG Children’s Cancer Study Group 
SEER Surveillance Epidemiology and End Results Program 
TRT Treatment-related toxicities 
CTCAE 3.0 Common Terminology Criteria for Adverse Events Version 3.0 
CR Complete remission 
ON Osteonecrosis 
SNPs Single nucleotide polymorphisms 
EFS Event-free survival 
OS Overall survival 
TS Thymidylate synthase  
PCR Polymerase chain reaction 
Abstract  
Purpose: This study compared the relative incidence of treatment-related toxicities and the 
event-free and overall survival between Hispanic and non-Hispanic children undergoing 
therapy for acute lymphoblastic leukemia (ALL) on Dana-Farber Cancer Institute ALL 
Consortium protocol 05-001. 
Patients and Methods: Secondary analysis of prospectively collected data from a phase III 
multi-center study in children and adolescents, 1 – 18 years with previously untreated ALL.   
Results: Between 2005 and 2011, 794 eligible patients enrolled on DFCI 05-001, 730 of 
whom were included in this analysis (19% [N=150] Hispanic, 73% [N=580] non-Hispanic). 
Hispanic patients were more likely to be ≥10 years of age (32% vs. 24%, p=0.045) at 
diagnosis. Toxicity analyses revealed that Hispanic patients had significantly lower 
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cumulative incidence of bone fracture (p<0.001) and osteonecrosis (p=0.047). In 
multivariable risk regression, the risk of osteonecrosis was significantly lower in Hispanic 
patients ≥10 years (HR 0.23; p=0.006). Hispanic patients had significantly lower 5-year 
event-free survival (EFS) (79.4%; 95% CI: 71.6% to 85.2%) and overall survival (OS) 
(89.2%; 95%CI: 82.7%-93.4%) than non-Hispanic patients (EFS: 87.5%; 95%CI: 84.5%-
90.0%, p=0.004. OS: 92.7%; 95%CI: 90.2%-94.6%), (p=0.006). Exploratory analyses 
revealed differences between Hispanic and non-Hispanic patients in the frequency of 
common variants in genes related to toxicity or ALL outcome. 
Conclusion: Hispanic children treated for ALL on DFCI 05-001 had fewer bone-related 
toxicities and inferior survival than non-Hispanic patients. While disease biology is one 
explanatory variable for outcome disparities, these findings suggest that biologic and non-
biologic mechanisms affecting drug delivery and exposure in this population may be 
important contributing factors as well. 
  
 
    
 




Despite overall cure rates near 90% in childhood acute lymphoblastic leukemia 
(ALL), survival in Hispanic children and adolescents remains inferior to survival in non-
Hispanic patients.1-4 These disparities are particularly striking in light of dramatic 
improvements in survival for all children with leukemia over the past three decades.5,6 In a 
large retrospective analysis from 12 Children’s Cancer Study Group (CCSG) ALL trials 
(1983-1995), 5-year event-free survival (EFS) was significantly lower in Hispanic children 
(65.9% ± 1.5%) when compared with 5-year EFS in white (72.8% ± 0.6%) and Asian children 
(75.1% ± 3.5%), (p<0.001).7 More recent studies, including a Surveillance Epidemiology and 
End Results (SEER) investigation of survival trends in ALL (1995-2012), have revealed a 
persistent survival difference (5-15 percentage points) between Hispanic and non-Hispanic 
children.1 The reasons for reduced survival in Hispanic children with ALL in North America 
are multifactorial and likely include both biologic and non-biologic factors, such as 
differences in the frequency of high-risk leukemia subtypes, host pharmacogenomics, 
reduced access-to-care, and non-adherence to oral chemotherapy.8  
Differences in survival outcomes between Hispanic and non-Hispanic patients with 
ALL have been described. 1,9-11 Fewer studies have investigated whether the incidence of 
TRT during ALL therapy varies by self-reported ethnicity, and none have described both 
survival and TRT in the same cohort. 9,12,13 The development of serious TRTs may result in 
an inability to tolerate full-dose chemotherapy, and the consequent interruptions in planned 
therapy (treatment delays, dose reductions) could theoretically contribute to increased risk of 
relapse.  Conversely, development of very few TRTs might indicate lower overall drug 
exposure, either due to genetic polymorphisms affecting drug metabolism or to non-biologic 
factors, such as chemotherapy non-adherence.   We conducted an analysis of TRTs and 
survival in Hispanic and non-Hispanic children and adolescents undergoing treatment for 
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newly diagnosed ALL on the Dana-Farber Cancer Institute ALL Consortium protocol 05-001 
(DFCI 05-001).14 We sought to compare the relative incidence of TRTs, EFS and overall 
survival (OS) between these two patient cohorts. Because common genetic variants are 
associated with risk of TRT,15,16 we also explored whether the prevalence of these 
polymorphisms in our patient population differed by ethnicity.  
Methods 
Patients and eligibility criteria 
 Children and adolescents aged 1-18 years with newly diagnosed ALL were enrolled 
on DFCI 05-001 at 11 sites in Canada and the United States, including Puerto Rico. Patients 
whose ethnicity was documented at the time of study enrollment were eligible for inclusion in 
this analysis. The Institutional Review Board of each participating institution approved the 
original treatment protocol and informed consent was obtained from each patient's guardian. 
All enrolled patients with known ethnicity (Hispanic and non-Hispanic) were included in the 
induction toxicity analysis.  Patients with a documented complete remission (CR), final risk 
group, and treatment assignment were included in post-induction treatment analyses. For 
the investigation of targeted genetic variants, patients who met the above criteria and who 
also had genomic DNA available for analysis were included.  
Ethnicity designation 
 Patient ethnicity (Hispanic or non-Hispanic) was documented at the time of study 
enrollment by a clinical research associate and was based on patient/parent report and/or 
patient’s country of origin, as was the standard during the period in which the clinical trial 
was conducted.17 Ethnicity designation was guided by the national standards for the 
classification of federal data on race and ethnicity as defined by the Office of Management 
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6 
and Budget (OMB) Statistical Policy Directive No. 15.18 Patients were categorized as 
underweight, normal, overweight and obese based on body mass index (BMI). For outcome 
analyses, patients were categorized as obese, (BMI ≥ the 95th percentile for age and sex) vs. 
not obese (BMI <95th percentile).  
Therapy 
 Details of the DFCI 05-001 treatment regimen have been previously published.14 In 
brief, all patients underwent multi-agent remission induction followed by risk-adapted post-
induction therapy based on final risk group assignment. Final risk group was based on age, 
presenting leukocyte count, immunophenotype, presence or absence of leukemia in the 
cerebrospinal fluid at diagnosis, leukemia-associated cytogenetic abnormalities, and end-
induction levels of minimal residual disease (MRD). All patients were scheduled to receive 
24 months of post-induction treatment. Patients were eligible to participate in a randomized 
comparison of intramuscular native E.coli L-asparaginase and intravenous pegaspargase 
during post-induction treatment. Patients who declined to participate, and those enrolled 
onto the trial after the randomized comparison had met its target accrual, were directly 
assigned to receive native E.coli L-asparaginase.  
Toxicity assessment 
 Treatment-related toxicities were defined using Common Terminology Criteria for 
Adverse Events (CTCAE) Version 3.0 and included: bone fracture (all grades), grade 2 or 
worse osteonecrosis (ON), grade 3 or worse infection (bacterial, fungal, viral and/or 
pneumocystis pneumonia), and grade 2 or worse asparaginase-associated toxicities (allergy, 
pancreatitis, thrombosis or bleeding).14 A diagnosis of bone fracture or ON required both 
clinical symptoms and radiographic confirmation. Study staff at each participating institution 
prospectively collected TRT data at the time of CR, every three months subsequently until 
 
    
 
This article is protected by copyright. All rights reserved. 
 
7 
treatment completion, and annually thereafter. 
Analysis of genetic variants 
We conducted a secondary analysis of genomic data that were gathered for a 
separate correlative study looking at toxicities in the same study population. In this study, 
toxicities were not analyzed by ethnicity. Genomic DNA was isolated from peripheral blood 
collected after patients achieved CR. Nineteen candidate genetic variants were selected for 
investigation through a non-exhaustive literature review, with the following criteria: (1) 
variants present in genes related to pathways presumed to be relevant to TRT; (2) variants 
known to be associated with altered function of the gene product; and (3) variants with a 
population prevalence of at least 10%.15,16 Single nucleotide polymorphisms (SNPs) were 
detected using polymerase chain reaction (PCR)-based allelic discrimination assays (Life 
Technologies, Grand Island, NY). The number of 28-bp repeats in the 5’ untranslated region 
of the thymidylate synthase (TS) gene was determined by PCR-product length analysis, as 
previously described.15 
Statistical methods 
Toxicity rates during induction and post-induction therapy were compared between 
groups with the Fisher’s exact test. In patients who were assigned a final risk group after 
achieving CR, ON and bone fracture with follow-up information were analyzed within age 
subgroups (<10 years vs. ≥10 years). The cumulative incidences of ON and fracture were 
estimated with the cuminc utility in the ‘cmprsk’ package in R and were tested using the Gray 
test, with relapse and death in remission identified as competing risks. Time-to-event was 
calculated as the time (years) from remission date to the date of first event.  If the bone 
event occurred in induction, it was considered an event at time 0. The cumulative incidence 
was also modeled in univariate and multivariable analyses using competing risks regression. 
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Multivariable models were adjusted for sex, asparaginase randomization, and final risk 
group. The grouping used in modeling for final risk group classification varied by age due to 
the protocol definition of age >10 as high risk.14  
Overall survival and EFS were estimated with the Kaplan-Meier method and were 
compared between groups with the log rank test. Overall survival was defined as the time 
from registration to death from any cause. Event-free survival was defined as the time from 
registration to the first event of relapse, death, or second malignancy. Induction events, 
including death and/or failure to achieve CR, were considered events at time 0. Cox 
proportional hazards models were used to model OS and EFS by group univariately and 
were adjusted in multivariable analyses for diagnostic age, immunophenotype, WBC, 
obesity, and sex. In patients receiving a single full dose of IV pegaspargase, a Wilcoxon rank 
sum test was used to compare the serum asparaginase activity (SAA) between Hispanic and 
non-Hispanic patients at days 4, 11, 18, and 25 during induction.  
The association between ethnicity group and SNPs were analyzed with the Fisher’s 
exact test. A false discovery rate (FDR), using the method of Benjamini and Hochberg19, was 
used to adjust for multiple comparisons. Comparisons padjusted<0.05 were considered 
significant. Additionally, an exploratory analysis was conducted to assess the univariate 
association between SNPs and toxicity (overall infection, pancreatitis, thrombosis, and 
allergy) within ethnicity group. The relationship between EFS and SNPs within these groups 
was also explored.  
Results 
Patient characteristics 
Between 2005 and 2011, 794 eligible children and adolescents (ages 1 – 18 years) 
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enrolled on DFCI 05-001, 730 of whom had ethnicity documented (150 [19%] Hispanic, 580 
[73%] non-Hispanic).  When compared with non-Hispanic children, a higher percentage of 
Hispanic patients were ≥10 years at the time of diagnosis (32% vs. 24%, p=0.045). A higher 
percentage of Hispanic patients were obese (20% vs. 12%, p=0.024). There was no 
significant difference in the presence or absence of the following leukemia-associated 
cytogenetic characteristics: high hyperdiploidy (51-65 chromosomes), BCR-ABL1, KMT2A 
(MLL)-rearrangement, hypodiploidy, and iAMP21 by ethnicity (Table 1).  Hispanic patients 
were significantly less likely to have the ETV6-RUNX1 fusion (p=0.018). Presenting 
leukocyte count, immunophenotype, National Cancer Institute (NCI) risk group, final DFCI 
risk group, or assigned randomized treatment arm (Table 1) did not significantly differ by 
ethnicity.  
Treatment-related toxicities 
Infection: The overall rate of infection during the induction treatment phase was not 
significantly different between Hispanic and non-Hispanic patients (25% vs. 29%, p=0.36).  
Hispanic patients trended toward having fewer bacterial infections than non-Hispanic 
patients (19% vs. 27%), but this difference was not statistically significant (p=0.07) (Table 2).  
Post-induction infections were documented in 31% of Hispanic patients and in 32% of non-
Hispanic patients (p=0.92) (Table 2).      
Asparaginase-associated toxicities: The overall incidence of post-induction 
asparaginase-associated toxicities including allergy, pancreatitis and thrombosis, was not 
significantly different between Hispanic and non-Hispanic patients (Table 2). The rate of ON 
and fracture during post induction therapy was lower in Hispanic patients (p=0.013 and 
<0.0001 respectively) (Table 2). 
Serum asparaginase activity (SAA): At least one induction SAA level was available in 
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318 patients. During remission induction, when all patients received a single dose of 
pegasapargase, we did not observe differences between Hispanic and non-Hispanic patients 
in median SAA levels at 4, 11, 18, and 25 days after the dose (Supplemental Figure S1).  
Osteonecrosis: Overall, the incidence of ON differed by age (p<0.0001) with patients 
≥10 years having more events. In patients ≥10 years of age, Hispanic ethnicity was 
associated with a significantly lower cumulative incidence of ON (hazard ratio, HR [95% 
confidence interval] 0.28 [0.10-0.76]; p=0.013; Fig. 1A). This result remained significant in 
multivariable modeling (p=0.006; Table 3). In patients <10 years of age there was no 
statistically significant difference in the rate of ON between Hispanic and non-Hispanic 
patients (0.61 [0.18-2.02], p=0.41, Fig. 1B).   Additionally, in competing risks regression 
there was no detectable difference in cumulative incidence of ON by obesity for each age 
group (Table 3). Analysis of SNPs revealed no significant difference between Hispanic and 
non-Hispanic patients in the frequency of the TS polymorphism, which we have previously 
shown is associated with risk of bone toxicity in this patient population.20,21 
Fracture: In patients ≥10 years of age, there was no significant difference fracture 
incidence between Hispanic and non-Hispanic patients (HR 0.63 [0.31-1.28], p=0.20 Fig. 
1C). In children <10 years, cumulative incidence of fracture was significantly lower in the 
Hispanic group (0.24 [0.10-0.54], p=0.0006; Fig.1D). This remained significant in 
multivariable modeling (p=0.0003; Table 3). In competing risks regression there was no 
detectable difference in cumulative incidence of fracture by obesity for each age group 
(Table 3).  
Survival 
The median follow-up time for those still alive was 6.12 years. Five-year OS was 
significantly lower in Hispanic patients (89.2% [82.7%-93.4%]) vs. non-Hispanic patients 
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(92.7 [90.2%-94.6%]), (p=0.006; Figure 2A). Five-year EFS was also significantly lower in 
Hispanic patients (79.4% [71.6%-85.2%]) vs. non-Hispanic patients (87.5% [84.5%-90.0%]), 
(p=0.004; Figure 2B). While both cohorts had nearly identical CR rates (94-95%), a higher 
percentage of Hispanic vs. non-Hispanic (13% vs. 9%) patients experienced disease relapse 
(Supplemental Table S1). There were no detectable differences in the site of relapse 
between groups (Supplemental Table S2). Of the B-ALL patients with a documented CR, 
there was no statistically significant difference in the proportion of patients with high end-
induction MRD (defined as ≥10-3): Hispanic (11%) vs. non-Hispanic (9%), p=0.55.  
Additionally, there was no difference in incidence of treatment-related mortality or in 
incidence of second malignant neoplasm between Hispanic and non-Hispanic patients.  
Ethnicity retained significance in multivariable Cox modeling for EFS (p=0.030) when 
adjusting for age, WBC, sex, immunophenotype and obesity, and marginal significance 
(p=0.07) in multivariable modeling for OS when adjusting for the same variables. In the 
multivariable models, obesity was significantly associated with OS (p=0.012) but EFS 
(p=0.27) (Table 4). 
Polymorphisms 
Genotyping data were available for 587 patients with ethnicity information, 574 of 
who received a final risk group classification (116 [20%] Hispanic, 458 [80%] non-Hispanic).  
After noting a difference in bone toxicity between Hispanic and non-Hispanic patients, we 
tested whether there was also a significant difference in the prevalence of a polymorphism in 
thymidylate synthase (TS) known to be associated with bone toxicity.16 In addition we tested 
whether there were disparities associated with ethnicity for 18 other TRT-related 
polymorphisms previously assessed in this cohort.15 Hispanic and non-Hispanic patients 
differed significantly in the proportion with the target genotype of four polymorphic genes: 
MTHFR A1298C (rs1801131; padjusted=0.001), SLCO2A1 (padjusted=0.003), IL1B 
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(padjusted=0.003), and TCN2 (padjusted=0.002) (Supplementary Table S3). Of these four 
polymorphisms, only TCN2 was associated with both TRT and disease outcome. In Hispanic 
patients, having (vs. not having) the target TCN2 genotype was associated with increased 
risk of induction infection (32% vs. 11%, p=0.010). In the Hispanic cohort, the TCN2 
polymorphism was univariately associated with EFS within the Hispanic patient cohort.  In 
multivariable modeling, TCN2 was marginally associated with EFS (HR=3.15, p=0.047) 
(Supplemental Table S4).  
Discussion 
This analysis of TRTs and survival from DFCI ALL 05-001 demonstrated that overall, 
Hispanic patients had lower rates of ON and fracture as well as reduced EFS and OS 
relative to non-Hispanic patients. The observation of both reduced toxicity and decreased 
survival in the Hispanic cohort suggests that host and/or environmental factors, rather than 
differences in leukemia biology alone, likely contributed to these outcomes.  
In our Hispanic cohort, the lower incidence of skeletal toxicity is suggestive of 
reduced exposure to dexamethasone, which may be related to variations in medication 
adherence or to variations in disease biology or host pharmacogenomics. A potential 
mechanism of reduced dexamethasone exposure is oral chemotherapy adherence. 
Chemotherapy agents that need to be orally administered at home, including 
mercaptopurine and corticosteroid, are important components of the treatment regimen for 
children and adolescents with ALL.17,22 In a 2012 report from the Children’s Oncology Group 
(COG), Bhatia and colleagues found that patients who were <95% adherent to 
mercaptopurine during maintenance therapy had a 2.5-fold higher risk of relapse than those 
who were ≥ 95% adherent.23 Further analyses revealed that Hispanic ethnicity, adolescent 
age ≥12 years and low socioeconomic status were all associated with lower adherence.23 Of 
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interest, the in patients with high adherence, Hispanic ethnicity was still associated with 
higher relapse rate. This further emphasizes the possibility that differential findings between 
Hispanic and non-Hispanic patients are likely driven in large part by biologic differences 
between groups, rather than only by differences in adherence.  In 2012, Kawedia, et al. 
reported that dexamethasone clearance may be higher in patients with anti-asparaginase 
antibodies.  In that study, the increased clearance and/or the presence of the antibodies 
were associated with a higher risk of relapse.24 Although we did not prospectively assess 
asparaginase antibodies on the 05-001 study, we serially measured SAA in patients during 
treatment,25 and demonstrated no differences in SAA between Hispanic and non-Hispanic 
patients, indicating similar exposure to this agent by ethnic group.  
Having identified reduced rates of ON in Hispanic patients, we were particularly 
interested in whether there were differences between cohorts in the frequency of an 
enhancer-repeat genotype (2R/2R) polymorphism in the TS gene.16,26 Our analysis did not 
identify a difference in prevalence of the 2R/2R TS polymorphism between Hispanic and 
non-Hispanic patients suggesting that either untested germline genetic factors or other 
variables beyond genetic polymorphisms may have contributed to differences in skeletal 
toxicities.27-29 The incidence of ON was significantly different between Hispanic and non-
Hispanic patients in the older (≥10 years of age) patients, and the incidence of fracture was 
significantly different between Hispanic patients and non-Hispanic patients, in the younger 
(<10 years of age) group. The association between older age and ON in ALL patients has 
been well-documented, as has the association between fracture and younger age.30,31 To 
our knowledge, no published study has identified a clear explanation for this phenomenon.  
Possible mechanisms may include hormonal interactions related to older age, timing of 
skeletal development, and unidentified genetic predispositions. Further, while obesity is a 
known predictor of reduced bone mineral density in children without leukemia,32 it was not 
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significantly predictive of either fracture or ON in our patient cohort and would not explain 
difference by age.  
While host genetic variations likely play an important role in determining drug 
pharmacokinetics and pharmacodynamics, somatic abnormalities in leukemia cells are 
critical determinants of response and resistance to therapy as well. Differences in the 
frequency of prognostically significant subtypes of ALL between Hispanic and non-Hispanic 
patients have been described, some of which could explain some of the outcome differences 
we observed.11,33 For example, we observed a significantly lower incidence of the favorable 
ETV6-RUNX1 (TEL/AML1) fusion, in our Hispanic cohort, which may have contributed to a 
higher risk of relapse.34  
We15,16 and others20,35-40  have previously described associations between functional 
genetic polymorphisms and TRT or survival among children with leukemia and the 
prevalence of some of these polymorphisms is known to differ between ethnic 
groups.11,20,33,41-43 In exploratory analyses, we targeted a small subset of polymorphisms that 
were relatively common (population prevalence of at least 10%) and that could potentially 
impact either TRT or survival.  We observed significant differences between Hispanic and 
non-Hispanic patients in the prevalence of four of the 19 polymorphisms analyzed 
(Supplemental Table 3) however, the clinical import of these germline genetic differences 
remains unclear.  The TCN2 rs1801198 polymorphism was more prevalent in Hispanic 
patients and was associated with inferior EFS within that cohort.  This polymorphism was 
also associated with increased risk of induction infection in the whole study population, but 
there was no significant difference in infection rates between Hispanic and non-Hispanic 
patients; in fact, Hispanic patients tended to have fewer bacterial infections overall.  
This study has some important limitations. First, the analysis of genetic 
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polymorphisms was not prospectively designed or powered to detect associations between 
all polymorphisms and uncommon outcomes. Additionally, we did not analyze incidence of 
poor prognostic indicators, including BCR-ABL1-like subtype and deletions of the Ikaros 
(IKZF1) gene, both of which have been reported to be more common in Hispanic patients.36-
38,41 These two features, which are frequently observed together, are independently 
associated with adverse outcomes in children with ALL. Thus, the inferior EFS and OS that 
we observed in Hispanic patients may be due to overrepresentation of these unfavorable 
biologic features within this population.44  While these alterations may have contributed to 
survival differences by ethnicity, they would not explain the difference in TRTs. 
Also, there was not a standard approach to designating patient ethnicity at the time of 
study enrollment. Hispanic ethnicity as a single broad category does not delineate between 
different Hispanic/Latino groups (e.g. Cuban, Mexican, Puerto Rican, South or Central 
American, Spanish), each of which are known to have unique biologic and non-biologic 
factors associated with disease outcome.45  Because of sample size limitations we did not 
analyze outcomes by combined race/ethnicity.  We acknowledge there are more objective 
ways of classifying patients’ ethnicity, for example by using genome-wide ancestry 
estimates. These methods, while precise in their characterization of genetic and biologic 
variation, are limited in their ability to account for sociocultural influences.45-48 For future 
studies, we will define both race and ethnicity using patient report, and will define genetic or 
biogeographical ancestry using modern genomic techniques.33,44 Comparing self-reported 
ethnicity to genetic ancestry will be an important part of investigating whether biology, 
sociocultural influences, or both, are contributing to observed outcome differences between 
ethnically distinct populations.49  
Conclusion 
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Hispanic children and adolescents enrolled on the DFCI 05-001 had significantly 
lower rates of skeletal toxicities as well as significantly lower EFS and OS compared to non-
Hispanic patients. Hispanic patients were more frequently obese than non-Hispanic patients 
and obesity was associated with inferior OS, it did not explain differences in ON, fracture or 
EFS by ethnicity. It is likely that the mechanisms behind our observations are a combination 
of biogeographical variables (i.e. inherited host genetic factors), gene-environment 
interactions, and sociocultural variables (i.e. early childhood exposures, baseline nutrition, 
health beliefs).50-52  
Other studies have compared self-defined ethnicity to genetic ancestry in childhood 
ALL, and have explored how these groups associate with relapse and adverse events.53 Our 
combined analyses of disease outcomes and toxicity in a homogeneously treated patient 
population suggests that factors beyond genomics are involved. Considering the observation 
of both reduced toxicities and inferior survival in the Hispanic cohort, the possibility of sub-
optimal drug exposure in these patients likely deserves further inquiry. Thus, while 
differences in both host and leukemia biology are prognostically important, future studies will 
focus on host pharmacogenomics, detailed analyses of nutrition status and obesity trends,54 
inter-patient differences in biomarkers of drug exposure, frequency of drug interruptions for 
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Figure legends:  
FIGURE 1: Probability of Osteonecrosis and Probability of Fracture by Age at Diagnosis 
(<10y vs. ≥10y) in Hispanic and Non-Hispanic Patients: Skeletal toxicity data are shown for 
(A) Osteonecrosis in patients ≥10 years of age (B) Osteonecrosis in patients <10 years of 
age (C) Bone fracture in patients ≥10 years of age, and (D) Bone fracture in patients <10 
years of age.  
 
FIGURE 2: Overall Survival and Event-Free Survival by Ethnicity: (A) Overall survival in 
Hispanic vs. non-Hispanic patients (B) Event-free survival in Hispanic vs. non-Hispanic 
patients. 
 
    
 




Supplemental Tables and Figure Legends 
Supplemental Table S1: Events in Hispanic and non-Hispanic patients.  
Both Hispanic and non-Hispanic patients had nearly identical complete remission (CR) rates 
(94-95%), however, a higher percentage of Hispanic vs. non-Hispanic (13% vs. 9%) patients 
experienced disease relapse.  
 
Supplemental Table S2: Distribution of sites of relapse by ethnicity. There was no significant 
difference in sites of relapse between Hispanic and non-Hispanic patients. 
 
Supplemental Table S3: Target polymorphisms by ethnicity.  
Hispanic and non-Hispanic patients differed significantly in the proportion with the target 
genotype of four polymorphic genes: MTHFR A1298C (rs1801131; padjusted=0.001), 
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SLCO2A1 (padjusted=0.003), IL1B (padjusted=0.003), and TCN2 (padjusted=0.002). 
 
Supplemental Table S4: Analyses of polymorphisms vs. disease-free survival (DFS) and 
event-free survival (EFS) in Hispanic and non-Hispanic patients with nominal p-values, 
overall and by ethnicity.  
In the Hispanic cohort, the TCN2 polymorphism was univariately associated with EFS within 
the Hispanic patient cohort.  In multivariable modeling, TCN2 was marginally associated with 
EFS (HR=3.15, p=0.05). 
 
Supplemental Figure S1: Median (IQR) Serum Asparaginase Activity levels in Hispanic and 
Non-Hispanic Patients: During remission induction, when all patients received a single dose 
of pegasapargase, median serum asparaginase activity (SAA) was measured 4 (D4), 11 
(D11), 18 (D18), and 25 (D25) days after the dose.  At least one induction SAA level was 
available in 318 patients. At D4, n=289, D11, n=318, D18 n=271, and D25 n=274.  We did 
not observed differences between Hispanic and non-Hispanic patients in median SAA levels 
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TABLE 1 Demographic and clinical characteristics of study participants on DFCI 05-001 
 Entire Cohort 
(With Ethnicity) 
Ethnicity  
Hispanic Non-Hispanic  
No. % No. % No. % p-value 
Cohort size 730 100 150 100 580 100 - 
Age, years       0.045 
     <10  545 75 102 68 443 76  
     ≥10  185 25 48 32 137 24  
White blood cell count (cells/μL)       0.57 
     <50,000 578 79 116 77 462 80  
     ≥50,000 152 21 34 23 118 20  
NCI risk group       0.19 
     Standard risk  445 61 84 56 361 62  
     High risk  285 39 66 44 219 38  
Immunophenotype       0.58 
     T-cell 89 12 16 11 73 13  
     B-cell 641 88 134 89 507 87  
Sex       0.52 
     Female 325 45 63 42 262 45  
     Male 405 55 87 58 318 55  
Body mass index (n=729)       0.053 
     Underweight 47 6 10 7 37 6  
     Normal 468 64 83 55 385 66  
     Overweight 112 15 26 17 86 15  
     Obese 102 14 30 20 72 12  
Cytogenetics
* 
       
     ETV6-RUNX1 136 17 18 12 118 20 0.018 
     High Hyperdiploidy  184 25 45 30 139 24 0.14 
 
    
 




     (51-65 chromosomes) 
     Ph+ (BCR-ABL-1) 19 3 4 3 15 3 1.00 
     KMT2A(MLL)-rearrangement 12 2 1 1 11 2 0.48 
     Hypodiploidy 10 1 1 1 9 2 0.70 
     iAMP21 12 2 1 1 11 2 0.48 
Achieved complete remission 695 95 141 94 554 96 0.36 
Final DFCI risk group
+
       0.81 
     Standard risk 370 54 71 51 299 54  
     High risk 242 35 54 39 188 34  
     Very high risk 62 9 12 9 50 9  
     Ph+ 16 2 3 2 13 2  
Asparaginase therapy
+
       0.75 
    Directly Assigned to IM E. Coli 267 39 52 37 215 39  
    Randomized to IM E. Coli 205 30 40 29 165 30  
    Randomized IV pegaspargase 218 32 48 34 170 31  
 
Abbreviations: NCI: National Cancer Institute; B-cell: B-cell acute lymphoblastic leukemia; T-cell: T-cell acute 
lymphoblastic leukemia; Ph+: Philadelphia chromosome positive ALL; iAMP21: Intrachromosomal amplification 
of chromosome 21; IM E.Coli: Intramuscular E. Coli asparaginase; IV Peg: IV pegaspargase;  
*n=12 not screened for cytogenetics including ETV6-RUNX1, high hyperdiploidy, KMT2A (MLL)-
rearrangement, hypodiploidy, and iAMP21 
+ Achieved a complete remission and assigned a post induction asparaginase group   
NCI risk group: Standard risk (WBC<50,000 and Age <10 years), High Risk (WBC≥50,000 or Age ≥10 years) 
 
    
 















Hispanic Non-Hispanic  
p-value No. % No. % No. % 
All 730 - 150 - 580 - - 
Infection 203 28 37 25 166 29 0.36 
     Bacterial 183 25 29 19 154 27 0.07 
     Fungal 30 4 8 5 22 4 0.36 
     Viral 5 <1 1 1 4 1 1.00 
     Opportunistic 3 <1 1 1 2 0 - 
Asparaginase toxicity 47 6 10 7 37 6 0.85 
     Pancreatitis 17 2 6 4 11 2 0.13 
     Allergy 10 1 2 1 8 1 1.00 
     Thrombosis 20 3 2 1 18 3 0.40 
Bone Event 3 <1 3 1 0 0 - 
     Bone Fracture 3 <1 3 1 0 0 - 









Hispanic Non-Hispanic  
p-value No. % No. % No. % 
All 690 - 140 - 550 - - 
Infection 220 32 44 31 176 32 0.92 
     Bacterial 158 23 30 21 128 23 0.74 
     Fungal 17 2 2 1 15 3 0.55 
     Viral 59 9 17 12 42 8 0.09 
 
    
 






     Opportunistic 21 3 1 1 20 4 0.10 
Asparaginase toxicity 183 27 40 29 143 26 0.59 
     Pancreatitis 75 11 20 14 55 10 0.17 
     Allergy 63 9 14 10 49 9 0.74 
     Thrombosis 72 10 11 8 61 11 0.35 
Bone Event* 163 24 15 11 148 27 <0.0001 
     Bone Fracture 131 19 11 8 120 22 <0.0001 
     Osteonecrosis 54 8 4 3 50 9 0.013 
* Only includes bone toxicity on therapy 
TABLE 3 Competing risks regression for skeletal toxicities by age subgroup and asparaginase treatment arm 
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Abbreviations: Direct assignment: Directly assigned to receive native E. Coli asparaginase IM E.Coli: Intramuscular E. 
 
    
 




TABLE 4 Cox proportional hazards univariate and multivariable models of overall survival (OS) 
and event-free survival (EFS) by ethnicity. BMI group was re-grouped to obese vs. not obese to 
account for overlap between obesity and overweight categories. No differences were seen with 
EFS. Adjusting for other variables, obesity remains significant and ethnicity is marginally 
significant. 
 Univariate Multivariable 
Hazard Ratio 
[95% CI] 
p-value Hazard Ratio 
 [95% CI] 
p-value 
Overall Survival (OS) 
 






























Event-Free Survival (EFS) 
 






























Abbreviations: WBC: White blood cell count; B-ALL: B-cell acute lymphoblastic leukemia; T-ALL: T-cell 
acute lymphoblastic leukemia 
 
 
Coli asparaginase; SR: Standard risk; VHR: Very high risk; ASP: asparaginase 
ⱡ Due to the small number of bone events (n<4) not considered in multivariable modeling  
